Ernexa Therapeutics Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ernexa Therapeutics Inc. on June 9, 2025. The filing reports the completion of the second closing of a private placement of equity securities and addresses the company's compliance status with Nasdaq listing requirements.
Key Financial Metrics and Capital Raise
- Total Gross Proceeds: Approximately $7.0 million from the aggregate issuance of 57,651,103 shares of common stock and 9,841,736 pre-funded warrants across two closings.
- Second Closing Proceeds: Approximately $6.0 million received on June 9, 2025, from the issuance of 47,717,087 shares and 9,332,000 pre-funded warrants.
- Outstanding Subscription: A remaining subscription amount of $190,248 for 1,818.815 shares has not yet been received.
- Stockholders' Equity: As of the filing date, the company reports stockholders' equity in excess of $2.5 million.
- Use of Proceeds: Net proceeds are intended for general working capital and repayment of certain notes.
Material Changes and Events
The primary material event is the completion of the second closing of a securities purchase agreement (SPA) originally entered into on March 31, 2025. This closing was contingent upon stockholder approval, which was obtained at the 2025 Annual Meeting of Stockholders on June 2, 2025. The issuance significantly increased the company's outstanding share count and capital base.
Outlook, Risks, and Nasdaq Compliance
Nasdaq Listing Status: On January 6, 2025, the company received notice of non-compliance with the Nasdaq Market Value of Listed Securities (MVLS) standard (minimum $35 million). The company had until July 7, 2025, to regain compliance.
Compliance Strategy: Following the capital raise, the company asserts it now meets the alternative "Stockholders' Equity Standard" (minimum $2.5 million) under Listing Rule 5550(b). The company intends to notify Nasdaq to determine if it has regained full compliance for continued listing on The Nasdaq Capital Market.
Security Terms: The pre-funded warrants are exercisable at a nominal price of $0.005 per share, subject to beneficial ownership limitations of 4.99% or 9.99%.
Investor Verification Checklist
- Confirm Nasdaq's official acceptance of the company's compliance with the Stockholders' Equity Standard.
- Verify the final receipt of the remaining $190,248 subscription amount.
- Review the updated capitalization table to assess dilution from the issuance of over 57 million shares and nearly 10 million pre-funded warrants.
- Monitor the company's cash burn rate and the specific notes being repaid with the new proceeds.